JPWO2020145227A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020145227A5
JPWO2020145227A5 JP2020565732A JP2020565732A JPWO2020145227A5 JP WO2020145227 A5 JPWO2020145227 A5 JP WO2020145227A5 JP 2020565732 A JP2020565732 A JP 2020565732A JP 2020565732 A JP2020565732 A JP 2020565732A JP WO2020145227 A5 JPWO2020145227 A5 JP WO2020145227A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence shown
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020565732A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020145227A1 (ja
JP7414370B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2020/000036 external-priority patent/WO2020145227A1/ja
Publication of JPWO2020145227A1 publication Critical patent/JPWO2020145227A1/ja
Publication of JPWO2020145227A5 publication Critical patent/JPWO2020145227A5/ja
Application granted granted Critical
Publication of JP7414370B2 publication Critical patent/JP7414370B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020565732A 2019-01-07 2020-01-06 配位子、スペーサー、ペプチドリンカーおよび生物分子からなる複合体 Active JP7414370B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2019000530 2019-01-07
JP2019000530 2019-01-07
JP2019206560 2019-11-14
JP2019206560 2019-11-14
PCT/JP2020/000036 WO2020145227A1 (ja) 2019-01-07 2020-01-06 配位子、スペーサー、ペプチドリンカーおよび生物分子からなる複合体

Publications (3)

Publication Number Publication Date
JPWO2020145227A1 JPWO2020145227A1 (ja) 2021-11-11
JPWO2020145227A5 true JPWO2020145227A5 (https=) 2022-10-24
JP7414370B2 JP7414370B2 (ja) 2024-01-16

Family

ID=71520276

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020565733A Pending JPWO2020145228A1 (ja) 2019-01-07 2020-01-06 配位子及びＣＥＡＣＡＭ５抗体Ｆａｂフラグメントからなる複合体
JP2020565732A Active JP7414370B2 (ja) 2019-01-07 2020-01-06 配位子、スペーサー、ペプチドリンカーおよび生物分子からなる複合体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020565733A Pending JPWO2020145228A1 (ja) 2019-01-07 2020-01-06 配位子及びＣＥＡＣＡＭ５抗体Ｆａｂフラグメントからなる複合体

Country Status (17)

Country Link
US (2) US20220096653A1 (https=)
EP (2) EP3909608A4 (https=)
JP (2) JPWO2020145228A1 (https=)
KR (2) KR20210113202A (https=)
CN (2) CN113301920B (https=)
AU (2) AU2020207081A1 (https=)
BR (2) BR112021013266A2 (https=)
CA (2) CA3125750A1 (https=)
CO (2) CO2021010116A2 (https=)
IL (2) IL284623B2 (https=)
JO (2) JOP20210183A1 (https=)
MX (2) MX2021008229A (https=)
PH (2) PH12021551631A1 (https=)
SG (2) SG11202107400QA (https=)
TW (2) TWI850308B (https=)
WO (2) WO2020145227A1 (https=)
ZA (2) ZA202105151B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI780082B (zh) 2016-11-18 2022-10-11 日商安斯泰來製藥股份有限公司 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
MX2020012351A (es) * 2018-05-17 2021-01-29 Astellas Pharma Inc Complejo que tiene fragmento fab de anticuerpo anti-muc1 de humano, enlazador peptido y/o ligando.
CA3115747A1 (en) 2018-10-10 2020-04-16 Astellas Pharma Inc. Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
CA3174082A1 (en) 2020-03-04 2021-09-10 Nihon Medi-Physics Co., Ltd. Compound and radioactive labeling compound
KR20230154183A (ko) 2021-03-04 2023-11-07 니혼 메디피직스 가부시키가이샤 화합물 및 방사성 표지 화합물
CN118852044A (zh) * 2021-09-03 2024-10-29 晶核生物医药科技(南京)有限公司 一种肽脲素衍生物、含其的药物组合物及其应用
EP4536278A2 (en) * 2022-06-07 2025-04-16 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
CA3265394A1 (en) * 2022-08-22 2024-02-29 Abdera Therapeutics Inc. VHH ANTIBODY CONJUGATES
WO2024235134A1 (zh) * 2023-05-12 2024-11-21 四川科伦博泰生物医药股份有限公司 具有靶向作用的偶联物及其制备方法和用途
WO2024243315A2 (en) * 2023-05-22 2024-11-28 Actinium Pharmaceuticals, Inc. Multi-arm bifunctional chelators
WO2025232116A1 (zh) * 2024-05-10 2025-11-13 四川科伦博泰生物医药股份有限公司 具有靶向作用的偶联物及其制备方法和用途
US12600794B2 (en) 2024-07-23 2026-04-14 Abdera Therapeutics Inc. 5T4 binding polypeptides and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
WO2005086875A2 (en) * 2004-03-11 2005-09-22 City Of Hope A humanized anti-cea t84.66 antibody and uses thereof
EP2083868A2 (en) 2006-10-04 2009-08-05 Københavns Universitet Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
JP5773352B2 (ja) 2008-10-28 2015-09-02 塩野義製薬株式会社 抗ｍｕｃ１抗体
CA2803520C (en) * 2009-07-08 2019-10-22 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
CN102666567B (zh) * 2009-12-04 2015-08-26 免疫医疗公司 用于蛋白质、肽和其它分子的改进的f-18标记的方法和组合物
EP2471557A1 (en) * 2010-12-27 2012-07-04 Università degli Studi di Genova A conjugate of human albumin and 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid useful for the localization of radionuclides for diagnostic and therapeutic purposes
KR102056932B1 (ko) * 2011-10-10 2019-12-17 시티 오브 호프 메디토프와 메디토프-결합 항체 및 이들의 용도
WO2013081091A1 (ja) 2011-12-01 2013-06-06 国立大学法人 千葉大学 非特異的腎集積が低減された放射性標識ポリペプチド作製用薬剤
MX379256B (es) * 2013-03-15 2025-03-10 Regeneron Pharma Moleculas biologicamente activas, conjugados de las mismas, y usos terapeuticos.
CN117138060A (zh) * 2014-10-07 2023-12-01 免疫医疗公司 抗体-药物缀合物的新辅助剂用途
CA2968990A1 (en) * 2015-01-09 2016-07-14 Immunomedics, Inc. Radiosensitivity of fluorophores and use of radioprotective agents for dual-modality imaging
WO2017150549A1 (ja) 2016-03-01 2017-09-08 国立大学法人 千葉大学 放射性標識薬剤
TWI780082B (zh) 2016-11-18 2022-10-11 日商安斯泰來製藥股份有限公司 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段
US10758632B2 (en) * 2017-02-06 2020-09-01 City Of Hope NIR-conjugated tumor-specific antibodies and uses thereof
JP7207740B2 (ja) 2017-09-26 2023-01-18 国立大学法人千葉大学 放射性薬剤

Similar Documents

Publication Publication Date Title
JPWO2020145227A5 (https=)
ES2595091T3 (es) Composiciones farmacéuticas con resistencia a CEA soluble
JP2020512281A5 (https=)
TWI780082B (zh) 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段
TWI795415B (zh) 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
RU2015116480A (ru) Анти-notch3 антитела и конъюганты антител с лекарственным средством
JPWO2020145228A5 (https=)
AU2016293606A1 (en) Cysteine-substituted immunoglobulins
JPWO2020145228A1 (ja) 配位子及びＣＥＡＣＡＭ５抗体Ｆａｂフラグメントからなる複合体
WO2003057838A2 (en) Antibodies against the muc18 antigen
JP7812336B2 (ja) 分子連結法または分子工学のためのタンデムリピートがん標的化ペプチドおよびがんセラノスティクスにおけるその使用
WO2023143365A1 (zh) Her3抗体药物偶联物及其用途
WO2023174401A1 (zh) Gpc3抗体药物偶联物及其用途
US20060051359A1 (en) Recombinant immunotoxin and use in treating tumors
Carrasquillo et al. Peritoneal carcinomatosis: imaging with intraperitoneal injection of I-131-labeled B72. 3 monoclonal antibody.
ES2278309T3 (es) Anticuerpos que modifican una enfermedad cancerosa.
JP2025524306A (ja) Ｉｔｇａ２を標的とする抗体及びそれを含む抗体薬物複合体
TW202116353A (zh) 使用酞菁染料靶向分子結合物之治療方法
EP4612189A1 (en) Radionuclide and near-infrared dye conjugated antibody for detection of gd2-positive cancer
KR20240099186A (ko) 알파-엽산 수용체에 대한 항체
JPWO2023125619A5 (https=)
JP2009529010A (ja) 癌性疾患修飾抗体
JP2025509338A (ja) Ｒｏｒ１標的結合分子とその使用
TW202607033A (zh) 抗ｒｏｒ２抗體－放射性核種結合物
US20220372125A1 (en) Antigen Specific Binding Domains and Antibody Molecules